Surprisingly, the efficacy of riluzole is independent of mGluR1 expression in breast cancer cells and is proposed to be responsible for alterations in cellular metabolism by inhibition of de novo pyrimidine synthesis and oxidative phosphorylation [163,164]. This evidence concerns the gene GRM1 and breast cancer.